文献速递浆细胞疾病造血干细胞移植与细胞治疗

伊德基仑赛治疗老年多发性骨髓瘤患者的临床结局:多中心真实世界经验

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心回顾性研究评估了156例接受商业化伊德基仑赛(ide-cel)治疗的多发性骨髓瘤患者,其中75例年龄≥65岁。老年患者(中位年龄69岁,66.7%衰弱,77.3%不符合KarMMa入组标准)最佳总缓解率为86.7%,中位无进展生存期9.1个月、总生存期26.5个月,≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征分别见于1%和4%;老年与年轻患者的安全性和疗效相似。

要点

  • 老年患者最佳总缓解率86.7%,与KarMMa研究结果(73%)相当。
  • 老年患者≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征分别占1%和4%。
  • 老年患者衰弱及多重用药、合并症、器官功能障碍等老年特征未导致总体结局更差。

核心结论

  • 伊德基仑赛在老年与年轻患者中的安全性和疗效相似,老年患者的衰弱及老年特征未带来更差的总体结局。

研究设计与样本

  • 多中心回顾性研究,共156例接受商业化伊德基仑赛输注的患者,其中75例年龄≥65岁;比较年轻(<65岁)与老年(≥65岁)患者的临床结局及衰弱和老年特征。

主要发现

  • 老年患者(中位年龄69岁,范围65-83岁;66.7%衰弱;77.3%不符合KarMMa入组标准)中位随访14.2个月,最佳总缓解率为86.7%,与KarMMa研究结果(73%)相当。
  • 老年患者中位无进展生存期为9.1个月,中位总生存期为26.5个月。
  • 老年患者≥3级细胞因子释放综合征发生率为1%,≥3级免疫效应细胞相关神经毒性综合征发生率为4%。
  • 与年轻患者相比,老年患者的衰弱及老年特征患病率显著更高:多重用药(≥5种药物)占97%,≥4种合并症占69%,器官功能障碍占35%(P < .05)。
  • 老年患者的衰弱及多重用药、合并症、器官功能障碍等老年特征未导致总体结局更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The safety and efficacy of chimeric antigen receptor T-cell therapy is not well described in older patients, a population that has higher frailty and comorbidities. In this multicenter retrospective study, we evaluated clinical outcomes along with frailty and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, and performance status in younger (aged <65 years) vs older (aged ≥65 years) patients who received commercial idecabtagene vicleucel (ide-cel). A total of 156 patients (n = 75, aged ≥65 years) were infused with ide-cel by data cutoff. In older patients (median age: 69 years; range, 65-83; 66.7% frail; 77.3% did not meet KarMMa eligibility criteria), with a median follow-up duration of 14.2 months, best overall response rate (ORR) was 86.7%, which was comparable with pivotal KarMMa study results (ORR: 73%). Median progression-free survival and overall survival in older patients were 9.1 months and 26.5 months, respectively. Grade ≥3 cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were observed in 1% and 4% of older patients, respectively. Compared with younger patients, the older patients had significantly higher prevalence of frailty, geriatric characteristics such as polypharmacy (≥5 drugs; 97%), ≥4 comorbidities (69%), and organ dysfunction (35%; P < .05). The safety and efficacy of ide-cel therapy were similar in younger and older patients. Frailty and geriatric characteristics such as polypharmacy, comorbidities, and organ dysfunction in older patients did not confer an inferior overall outcome.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kalariya NM, Hildebrandt MAT, Hansen DK, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024. PMID: 39042903. doi:10.1182/bloodadvances.2024013540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。